ProSAAS is a neuroendocrine peptide precursor that potently inhibits prohormone convertase 1 in vitro. To explore the function of proSAAS and its derived peptides, transgenic mice were created which express proSAAS using the beta-actin promoter. The body weight of transgenic mice was normal until approximately 10-12 weeks, and then increased 30-50% over wild-type littermates. Adult transgenic mice had a fat mass approximately twice that of wild-type mice, and fasting blood glucose levels were slightly elevated. In the pituitary, the levels of several fully processed peptides in transgenic mice were not reduced compared with wild-type mice, indicating that the proSAAS transgene did not affect prohormone convertase 1 activity in this tissue.
Introduction
Most neuropeptides, and many other proteins that transit the secretory pathway, are originally produced as precursors that undergo selected proteolysis. In many cases, the processing occurs at sites containing basic amino acids. First, a prohormone/proprotein convertase (PC) cleaves at the C-terminal side of the basic residue(s). Then, a carboxypeptidase (CP) removes the C-terminal basic amino acids. Several PCs have been reported, including PC1, PC2, and five others (Seidah & Chretien 1998a ,b, Zhou et al. 1999 . In contrast to the relatively large number of PCs, only two CPs appear to function in the removal of C-terminal basic residues in the secretory pathway: CPE and CPD (Fricker 1998a (Fricker ,b, 2002 . These enzymes differ in their primary site of action, with CPE more active at the acidic pH of the post-Golgi secretory vesicles, while CPD functions in the trans-Golgi network as well as within the exocytic and endocytic pathways.
Mice deficient in CPE activity due to a naturally occurring point mutation (i.e. the Cpe fat/fat mice) show a decrease in fully processed peptides and a large increase in the levels of processing intermediates containing C-terminal basic residues (Naggert et al. 1995 , Fricker et al. 1996 , Rovere et al. 1996 , Cain et al. 1997 , Udupi et al. 1997 .
Several proSAAS-derived peptides were discovered using a strategy to isolate peptide substrates of CPE, based on their accumulation in Cpe fat/fat mice , Che et al. 2001 . These peptides included big SAAS, little SAAS, and little LEN with C-terminal Arg-Arg extensions, PEN with a Lys-Arg extension, and KEP with an Arg extension . Further studies in wild-type mice (Mzhavia et al. 2001) and in neuroendocrine cell lines (Mzhavia et al. 2002) showed that the major forms of these peptides lacked C-terminal basic residues, and also revealed additional peptides that were generated from proSAAS ( Fig. 1) . Although the proSAAS protein does not have significant sequence similarity to any other entry in the GenBank database, the general size, amino acid composition, and distribution of the proSAAS protein are similar to that of 7B2, an endogenous inhibitor of PC2 (Marcinkiewicz et al. 1987 , Martens et al. 1994 , Cameron et al. 2000 . ProSAAS was found to potently inhibit PC1 in vitro , and further studies determined that the inhibitory region of proSAAS was the 6-8 amino acid region surrounding the junction of PEN and LEN (Cameron et al. 2000 , Basak et al. 2001 . Thus, while big and little forms of PEN-LEN inhibit PC1 with low nanomolar affinity, fully processed LEN and PEN are inactive as inhibitors. Interestingly, PEN-Lys-Arg is also a potent inhibitor of PC1, indicating that the carboxypeptidase step is important in regulating the PC1-inhibitory activity of this peptide (Cameron et al. 2000) .
Because only a relatively small region of proSAAS functions as a PC1 inhibitor, and several of the other regions are highly conserved between human and rodents, it is likely that proSAAS-derived peptides perform additional functions, possibly as neuropeptides. Recently, proSAAS was identified in a screen of proteins that are altered in the cerebrospinal fluid of people with frontotemporal dementia (Davidsson et al. 2002) . The level of a 20 kDa fragment of proSAAS was decreased approximately 75% in the patients with frontotemporal dementia, although it is not clear if the changes in proSAAS contribute in any way to the dementia or are merely secondary changes as a result of the disease. To gain insights into possible functions of proSAAS-derived peptides, we created transgenic mice overexpressing pro-SAAS. In addition to expressing the transgene in mice with normal levels of CPE, we also expressed the pro-SAAS transgene in CPE deficient Cpe fat/fat mice in order to increase the levels of PEN-Lys-Arg and thus produce a greater inhibition of PC1.
Materials and Methods

Creation of transgenic mice
All animal experimentation described in this report was conducted in accord with accepted standards of humane animal care, as outlined in the Ethical Guidelines of the Albert Einstein College of Medicine. A construct utilizing Figure 1 (A) Schematic diagram of proSAAS and the location of various proSAAS-derived peptides within this precursor. Singleand di-basic cleavage sites within proSAAS that give rise to the various peptides are indicated. Big PEN-LEN, little PEN-LEN, and PEN with a Lys-Arg extension on the C-terminus are the only proSAAS-derived peptides found to inhibit PC1. (B) Schematic diagram of the transgenic construct, which consisted of the beta-actin promoter and 5 flanking region (3 kb), the untranslated beta-actin exon 1 (78 bp), the beta-actin intron and enhancer element (1 kb), rat proSAAS cDNA (1 kb) and the SV40 polyadenylation site (0·3 kb).
the -actin promoter (Graham et al. 1997) to drive expression of full-length rat proSAAS cDNA (Fig. 1B ) was used to create proSAAS transgenic mice in the B6D2F1 strain. Three hemizygous founder mice were demonstrated to be transgenic proSAAS-positive. Transgenic mouse line 32 (deriving from founder mouse #32) was further bred for several generations in the BDF strain and then backcrossed to the C57 BKS strain for five generations. Mice were maintained in a daily cycle of 12 h light/12 h darkness and allowed free access to water and chow (Lab diet 
Analysis of proSAAS mRNA and peptide levels
Oligonucleotide primers and fluorogenic probe combinations for TaqMan assays were designed using Primer Express v1·0 (Applied Biosystems, Foster City, CA, USA). For detection of endogenous mouse proSAAS mRNA, the forward primer (5 -AGGAGGCCGAGAG ACAGGAA-3 ), reverse primer (5 -GCGCCTGCTGA TCCTCA-3 ), and probe (5 -FAM-CTCCTGCGCCT CAGCACGCG-TAMRA-3 ) were specific for mouse SAAS and did not amplify the rat SAAS transgene. Rat SAAS transgene expression was detected by a forward primer (5 -CCAGACATGATAAGATACATTGATGA GTTT-3 ), reverse primer (5 -AAAGCAATAGCATCA CAAATTTCACA-3 ), and probe (5 -FAM-ACAAA CCACAACTAGAATGCAGTGAAAAAAATGCTTT TAMRA-3 ) designed against the SV40 poly-A portion of the rat proSAAS transgene construct. These primers did not produce any PCR amplification product in samples from Tg mice. All proSAAS TaqMan reactions were normalized against the expression levels of mouse cyclophilin mRNA using a forward primer (5 -CAAATG CTGGACCAAACACAA-3 ), reverse primer (5 -GCCTTCTTTCACCTTCCCAAA-3 ), and probe (5 -FAMTTCCCAGTTTTTTATCTGCACTGCCAAGA TAMRA-3 ) specific for mouse cyclophilin. Total RNA was isolated from whole mouse brains using Trizol reagent (Invitrogen) according to the manufacturer's instructions, and treated with DNaseI (Invitrogen) prior to reverse transcription to remove contaminating DNA. Reverse transcription was performed with 5 µg total RNA using the Superscript Preamplification System for First Strand cDNA Synthesis (Invitrogen) according to the supplier's protocol, and diluted in water to a final volume of 300 µl.
Quantitative real-time PCR assays were performed using the ABI PRISM 7700 TaqMan sequence detector and Sequence Detector v1·6 (Applied Biosystems). Reactions were performed in triplicate using the TaqMan PCR Core Reagent kit (Applied Biosystems). Each reaction contained 1 TaqMan buffer A, 5 mM MgCl 2 , 0·2 mM each of dATP, dCTP, dGTP, dUTP, 70 nM each of the forward and reverse primer, 100 nM probe, 0·5 U Amperase UNG, 1·25 U AmpliTaq Gold, and 10 µl first strand cDNA in a final volume of 50 µl. Thermal cycling conditions were 2 min at 50 C, 10 min at 95 C followed by 40 cycles of 15 s at 95 C and 1 min at 60 C.
For analysis of proSAAS peptides, brains were frozen in liquid nitrogen and ground into a fine powder. Ten volumes 0·1 M boiling acetic acid were added, and then the samples were mixed, incubated for 15 min at 100 C, cooled on ice, and centrifuged for 30 min at 12 000 g. The supernatants were removed, dried in a vacuum centrifuge, and rehydrated in buffer A (100 mM sodium phosphate pH 7·4 containing 0·1% Triton X-100). The samples were applied to a Superdex Peptide HR 10/30 gel-exclusion column (Amersham Bioscience) and fractionated in 30% acetonitrile and 0·1% trifluoroacetic acid. The flow rate was 0·5 ml/min. One-minute fractions were collected, dried, and resuspended in buffer A. Immunoreactive-(ir-) LEN peptide was determined by radioimmunoassay (RIA) using an antiserum to big LEN (rabbit number 85) as described previously (Mzhavia et al. 2001) .
Food consumption and body fat determination
Total cumulative food consumption was measured for one week in individually housed female proSAAS Tg + and Tg mice that were 10 weeks of age. Average daily consumption was determined (g/day).
For the determination of body fat, five male proSAAS Tg + and five age-matched Tg Cpe +/+ mice were killed with CO 2 vapors. The inguinal, retroperitoneal, scapular, reproductive and mesenteric fat pads were removed and weighed. The individual weight of each fat pad was calculated as a percentage of total body weight. The results were analyzed using Student's t-test. For analysis of fasting glucose levels, mice were deprived of food from 2200 h and blood was taken at 1000 h the next day. Approximately 50 µl blood were withdrawn from the tail using a heparinized microhematocrit capillary tube (Fisher Scientific, Pittsburgh, PA, USA) and transferred to a polyethylene heparinlithium coated microfuge tube (Beckman Instrument Inc. Palo Alto, CA, USA). Plasma was collected after centrifugation at 7200 g for 5 min. Fasting glucose levels were analyzed using Glucose Analyzer 2 (Beckman Instrument Inc.).
Analysis of plasma levels of glucose and other substances
Insulin levels were measured by RIA using an antiserum raised against rat insulin which cross reacts 100% with mouse insulin (Linco Research, St Charles, MO, USA). The cross reactivity of this antiserum to mouse proinsulin and to mouse proinsulin-processing intermediates is unknown; this antiserum has a 69% cross reactivity to human proinsulin.
Analysis of relative levels of pituitary peptides
In order to quantitate peptide levels using mass spectrometry, we used a quantitative peptidomics strategy that employs differential isotopic labels (H 6 and D 6 -Ac 2 O) as described (Che & Fricker 2002 ). The tissue was incubated in a boiling water bath for 10 min and then sonicated for 5 s. The HCl extract was neutralized with 1 µl 1·0 M NaOH followed by the addition of 200 µl 0·2 M NH 4 HCO 3 , pH 7·5. Acetylation was carried out by adding 12 µl H 6 -Ac 2 O or D 6 -Ac 2 O to the homogenate. For normal labeling, the Tg extract was labeled with H 6 -Ac 2 O while the Tg + extract was labeled with D 6 -Ac 2 O. For reverse labeling, the Tg extract was labeled with D 6 -Ac 2 O while the Tg + extract was labeled with H 6 -Ac 2 O. Generally, normal labeling was carried out for half of the Tg + and Tg mice and reverse labeling for the other half of the mice. After acetylation, the H 6 -Ac 2 Olabeled samples and the D 6 -Ac 2 O-labeled samples from age-and sex-matched mice were pooled and centrifuged at 50 000 g for 30 min at 4 C. The supernatant was removed and filtered through a Centricon YM-10 membrane (Amicon. Beverly, MA, USA). Finally, the filtrate was desalted with ZipTip C 18 (Millipore, Billerica, MA, USA) and analyzed by matrix-assisted laser desorption ionization, time-of-flight, mass spectrometry (MALDI-TOF-MS).
MALDI-TOF-MS analysis was performed in the delayed extraction linear positive mode on a Voyager-DE STR mass spectrometer (PerSeptive Biosystems, Framingham, MA, USA). Typically, aliquots (0·5 µl) of ZipTip C 18 desalted sample were mixed with 1 µl 5 mg/ ml -cyano-4-hydroxycinnamic acid in 50% acetonitrile and 0·1% trifluoroacetic acid. + and Tg mice were measured by the ratio of peak intensity of the H 3 -Ac-and D 3 -Ac-labeled peptide pairs, as described (Che & Fricker 2002) . Peptides were identified by comparing the observed parent mass of each peptide (after subtraction of the added acetyl groups) to the theoretical mass of peptides that were previously identified in pituitary extracts (Feistner et al. 1989 , Young et al. 1993 , Jimenez et al. 1997 , Che et al. 2001 , Che & Fricker 2002 .
Immunohistochemistry of proinsulin in pancreas
For immunohistochemistry, 5-µm thick sections of paraffin-embedded pancreas from age-and sex-matched animals were deparaffinized with two changes of xylene and rehydrated. The slides were bathed in 3% H 2 O 2 for 15 min at 37 C to quench endogenous peroxidase and then heated in a microwave oven in citrate antigen retrieval solution (0·1 M sodium citrate, pH 6·0, with 0·01% Triton X-100) to allow the epitopes to reconfigure. Sections were incubated for 2 h at room temperature in blocking buffer (NEN Life Science, Boston, MA, USA) containing a 1:2000 dilution of monoclonal mouse anti-human proinsulin antibody (the gift of Dr Ole Madsen, Hagedorn Research Institute, Gentofte, Denmark). Sections were washed in phosphate-buffered saline with 0·2% Tween-20, pH 7·4, exposed to biotinylated anti-mouse immunoglobulin (DAKO LSAB system, Glostrup, Denmark) for 20 min, washed, followed by incubation in streptavidin-horseradish peroxidase for 20 min and washed in the same buffer. The staining was visualized with liquid diaminobenzidine chromogen for 2 min and stopped by washing in water. The slides were then counterstained and observed under a light microscope. The images were captured from an attached camera using Kodak Ektachrome 64T film.
Western blot analysis of PC1
Brain tissues were frozen in liquid nitrogen, ground to a fine powder, and homogenized in 10 volumes 50 mM Tris-HCl pH 7·4 containing 1% Triton X-100, 10% glycerol, and a protease inhibitor cocktail (Sigma P8340). Homogenates were kept on ice for 30 min to allow proteins to solubilize and then fractionated on an SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was probed with a 1:1000 dilution of rabbit polyclonal antiserum raised against the N-terminal region of PC1 (Vindrola & Lindberg 1992) . Equal loading was confirmed by blotting with anti-tubulin antiserum (Sigma).
Results
Three founder mice were positive for proSAAS expression. One of these was extremely obese (approximately 70 g at 45 weeks) but was sterile. Post-mortem analysis using real-time quantitative PCR revealed that the level of proSAAS mRNA in the brain of this mouse was fivefold higher than in wild-type mice (data not shown). A second mouse (#32) was fertile and moderately overweight, and expressed proSAAS mRNA in the brain at a level approximately twofold that of wild-type mice (data not shown). A third proSAAS-positive mouse (#29) was also fertile but was not overweight. This mouse expressed proSAAS mRNA in the brain at a level that was not substantially different from wild-type mice; this line was not investigated further.
Mouse #32 was crossed into the C57 BKS background, which is more sensitive to the development of hyperglycemia than other strains (Naggert et al. 1995) . Also, this strain was chosen so that the transgene could also be expressed in CPE-deficient Cpe fat/fat C57 BKS mice. In proSAAS transgene-positive CPE-normal C57 BKS mice (Tg + Cpe +/+ mice), the level in brain of ir-LEN, a proSAAS-derived peptide, was elevated 60-90% over the level in Tg Cpe +/+ mice. The processing of proSAAS in brain was examined using gel filtration followed by RIA. The size of the ir-LEN in the proSAAS Tg + mice was identical to that in Tg mice (Fig. 2) , indicating that the overexpression does not lead to any alteration in the extent of the processing.
The transgenic mice were born in the expected frequency. mice was lower than that of the Tg Cpe fat/fat mice (Fig.  4, panels C and D) . However, these differences were not statistically significant due to the small number of animals that survived past 16 weeks. Analysis of individual mice showed a dramatic loss in weight in the week or two before death.
Individual fat pads from Tg + and Tg Cpe +/+ mice were isolated and compared. The inguinal and reproductive fat pads from the Tg + mice were approximately twice the fraction of body weight of the comparable fat pads from Tg mice (Fig. 5) . The scapular, the retroperitoneal and the mesenteric fat pads also showed a tendency to be larger in the Tg + mice, although the differences were not statistically significant (Fig. 5) .
To determine if there were any major differences in serum chemistry, plasma samples from a small number of animals were analyzed (Table 1) . Serum glucose levels were higher in the Cpe fat/fat mice relative to the Cpe +/+ mice, as previously reported (Naggert et al. 1995 , Leiter et al. 1999 , and the presence of the proSAAS transgene further elevated this parameter to .1000 mg/dl ( (Table 1) . To further examine the effect of the transgene on glucose levels, fasted animals were examined for serum glucose levels. There was a small but statistically significant + Cpe fat/fat mice (square symbols, panels C and D) the number of animals decreased substantially throughout the study due to the high mortality rate (Fig. 3 ) and the last 2-4 measurements of these groups represent single animals.
increase in fasting serum glucose levels in both male and female Tg + Cpe +/+ mice, relative to Tg Cpe +/+ mice (Fig. 6 ). As previously found (Naggert et al. 1995 , Leiter et al. 1999 ), the fasting serum glucose level in male Cpe fat/fat mice was higher than in female Cpe fat/fat mice. The proSAAS transgene further elevated serum glucose in both male and female Cpe fat/fat mice, although this increase was only statistically significant in the female mice (Fig. 6) .
Serum insulin levels were examined in proSAAS Tg + and Tg Cpe +/+ mice following a 4-h fast (Table 2) . Although the 4·5 to 6 month old Tg + females showed a tendency for lower insulin levels than the Tg mice, this difference was not statistically significant. The male Tg + mice showed a tendency for higher insulin levels at the same time point, but this also was not statistically significant. Because the RIA for insulin detects human proinsulin and the processing intermediates, and therefore presumably also detects mouse proinsulin and intermediates, we also examined the pancreas of the various lines of mice using a mouse monoclonal antibody specific for proinsulin (Orci et al. 1985) . The islets in Tg Cpe +/+ mice showed only weak and scattered ir-proinsulin (Fig.  7A) for proinsulin (Fig. 7B) , consistent with a decrease in the processing of proinsulin into insulin due to inhibition of PC1 by the elevated proSAAS expression in these mice. CPE-deficient Cpe fat/fat mice showed strong staining for proinsulin (Fig. 7C,D) , consistent with a previous report that these mice do not efficiently process proinsulin into insulin (Naggert et al. 1995 mice, nine distinct peptides were observed that were quantifiable (i.e. the heavy and light peaks were sufficiently separated to permit measurement of peak intensity), ranging in mass from 739·35 to 2772·56 Da (Table 3) . Five of these peptides correspond to the mature forms of peptides previously identified in Cpe fat/fat mice pituitaries and which were sequenced using tandem mass spectrometry (Che et al. 2001) . Of the four additional 'unknowns,' one of these corresponds to the theoretical mass of mouse gamma-melanocyte stimulating hormone (gamma-MSH; 1337·75 Da observed, 1337·63 Da theoretical), but since it was not sequenced by tandem mass spectrometry, it is listed as 'unknown'. Interestingly, none of the nine observed peptides is decreased in the Tg + Cpe +/+ mice, relative to the Tg Cpe +/+ mice (Table 3) . Instead, the peptide levels are either unchanged (vasopressin and three of the unknowns) or significantly elevated (the four pro-opiomelanocortinderived peptides and the 1337·75 Da unknown peptide, which may represent the gamma-MSH fragment of proopiomelanocortin). This result implies that the level of proSAAS expression in the pituitary of Cpe +/+ does not inhibit PC1 activity, and that the proSAAS transgene stimulated the expression of pro-opiomelanocortinderived peptides. In contrast to the results in Cpe +/+ mice, when expressed in CPE-deficient Cpe fat/fat mice the transgene significantly decreased the levels of vasopressin, J-peptide, corticotropin-like intermediate lobe peptide, and the 2772·56 Da unknown peptide (Table 3) (Naggert et al. 1995 , Fricker et al. 1996 , Rovere et al. 1996 , Cain et al. 1997 , Udupi et al. 1997 , Che et al. 2001 . The transgene-induced decrease in pituitary peptide levels in Cpe fat/fat mice is consistent with the inhibition of PC1 in the proSAAS-expressing mice.
The levels and forms of PC1 in brain of the various mice were examined by Western blotting with a C-terminally directed antiserum. As previously reported (Berman et al. 2001) , the 68 kDa form of PC1 is the predominant form in Tg Cpe +/+ and Tg Cpe fat/+ mice (Fig. 8) . In Tg Cpe fat/fat mice, there is less of the 68 kDa form and more of the 84 kDa form, in addition to a larger form (Fig. 8) . This larger form is only detected in the Cpe fat/fat mouse extract, and may correspond to an intermediate proPC1 form with unprocessed N-linked glycosylation. The relative level of the various forms of PC1 is not influenced by the presence or absence of the proSAAS transgene (compare lanes 1 and 2 or lanes 3 and 4, Fig. 8) . Thus, the effect of the proSAAS transgene on the apparent PC1 activity is not due to alterations in the levels or forms of PC1 protein.
Discussion
Although proSAAS-derived peptides were initially discovered in Cpe fat/fat mice which show adolescent-onset obesity, it was not clear whether these peptides contributed to the obesity phenotype. A large number of known peptides were also identified using the same technique that was used to discover the proSAAS-derived peptides , Che et al. 2001 , and many of these other peptides are not thought to be involved in body weight regulation. Based on the previous finding that proSAAS and some proSAAS-derived peptides potently inhibit PC1, it was predicted that proSAAS transgenic mice would resemble mice with a disruption in the PC1 gene (PC1 knock-out (KO) mice). However, the phenotype of PC1 KO mice is much different from that observed for the proSAAS transgenic mice. The PC1 KO mice are much smaller than wild-type mice, presumably due to a deficiency in growth hormone-releasing hormone production (Zhu et al. 2002a) . A human mutation of PC1 has been reported to have the opposite phenotypeextreme, early-onset obesity (Jackson et al. 1997) . This also differs from the moderate adolescence-onset obesity observed in the proSAAS Tg + mice. Taken together with our finding that proSAAS Tg + Cpe +/+ mice are not defective in their processing of pituitary peptides, it suggests that the level of proSAAS expression in the transgenic mice is not sufficient to substantially impair PC1 activity in the pituitary. Thus, the moderate obesity observed in these mice is likely due to another action of proSAAS and/or the proSAAS-derived peptides, possibly as neuropeptides. In addition to the evidence cited above, it is unlikely that the proSAAS transgene-mediated increase in body weight observed in the Cpe +/+ mice is due to inhibition of PC1 because this phenotype is not more pronounced in the Tg + Cpe fat/fat mice, which clearly have a greater impairment of PC1 activity than the Tg + Cpe +/+ mice. 
possible gamma-MSH related pro-opiomelanocortin peptide KYVMGHFRWD (1337·63 m). *P<0·05; **P<0·01 compared with standard peptides tested at equimolar amounts (e.g. a ratio of 1·0).
Figure 8 Western blot analysis of PC1 in proSAAS Tg
+ and Tg mice. Brain extracts were fractionated on a denaturing 8% polyacrylamide gel, transferred to nitrocellulose, and probed with an antiserum raised against the N-terminal region of PC1. The genotype is shown at the top of the figure. The positions and masses (in kDa) of the prestained protein standards are indicated. The experiment was replicated twice with additional animals and similar results were obtained.
ProSAAS mRNA and proSAAS-derived peptides are present at relatively high levels in the hypothalamus, and in particular in nuclei implicated in body weight regulation , Feng et al. 2001 . A large number of other peptides have been implicated in the regulation of body weight, including neuropeptide Y, galanin, melanocyte-stimulating hormone, melanin-concentrating hormone, cocaine-and amphetamine-regulated transcript, agouti-related peptide, corticotropin-releasing hormone, glucagon-like peptide-1, urocortin, leptin, ghrelin, and several others (Qu et al. 1996 , Spina et al. 1996 , Turton et al. 1996 , Mizuno et al. 1999 , Altman 2002 , Schwartz & Morton 2002 , Torri et al. 2002 , Wilding 2002 . Some of these were first identified as candidates for body weight regulation from studies involving transgenic or knock-out mice. In contrast, other peptides that cause substantial changes in body weight when administered to mice or rats fail to alter body weight when the gene is disrupted (Erickson et al. 1996) . Thus, the regulation of body weight is a very complex system that shows plasticity, an inherent problem in studies using transgenic and/or knock-out mice. In addition to the various peptides, other gene products have been implicated in body weight regulation from studies involving transgenic mice, knock-out mice, or mice with naturally-occurring mutations; examples include various receptors (Chen et al. 1996 , Huszar et al. 1997 , Chen et al. 2000 , Marsh et al. 2002 , secreted proteins (Hahm et al. 1999 , Collier et al. 2000 , and enzymes (Naggert et al. 1995 , Masuzaki et al. 2001 .
The increase in pro-opiomelanocortin-derived peptides in the proSAAS-Tg + Cpe +/+ mice is clearly not the result of inhibition of PC1 activity; these peptides are terminal processing products and not just intermediates in the processing pathway. Also, because the levels of vasopressin and three of the unidentified peptides were not substantially affected by the expression of the proSAAS transgene, it is unlikely that there was significant inhibition of PC1 in the Cpe +/+ mice pituitary. Instead, it is possible that pro-opiomelanocortin gene expression was induced, either directly as a result of the elevated levels of proSAASderived peptides, or indirectly due to a consequence of the proSAAS expression. Further studies are needed to investigate whether pro-opiomelanocortin mRNA is directly elevated by proSAAS expression, and to determine the mechanism of the apparent increase in proopiomelanocortin-derived peptides in proSAAS transgenic animals. Interestingly, pro-opiomelanocortin mRNA levels are substantially elevated in mice with a disruption in the PC1 gene (Zhu et al. 2002a,b) .
The decrease in vasopressin levels in the proSAAS-Tg + Cpe fat/fat mice, relative to Tg Cpe fat/fat mice, is consistent with a role for PC1 in the processing of provasopressin. PC1 has been co-localized with provasopressin in the hypothalamic nuclei that project to the posterior pituitary (Dong et al. 1997) . In addition, PC2 and other related PCs are expressed in the provasopressin-containing nuclei (Dong et al. 1997) , suggesting that multiple enzymes contribute towards the processing of this precursor. Similarly, pro-opiomelanocortin-expressing cells in the intermediate lobe of the pituitary also express both PC1 and PC2, and both enzymes are thought to be involved in pro-opiomelanocortin processing. Because proSAAS and the PEN-containing processing intermediates (Fig. 1) are relatively selective as inhibitors of PC1 , Basak et al. 2001 , the overexpression of proSAAS in the Cpe fat/fat mice would presumably only reduce PC1 activity. If this is correct, then PC1 contributes to at least 50% of the processing of provasopressin into vasopressin and pro-opiomelanocortin into J-peptide, based on the decrease of these peptides in proSAAS Tg + mice relative to Tg Cpe fat/fat mice. The three founder mice showed a strong correlation between the level of proSAAS expression in the brain and the degree of obesity, with the highest expresser approximately 70 g at 45 weeks of age. Unfortunately, this mouse was not fertile. Although the fertile male that expressed moderately elevated levels of proSAAS mRNA (mouse 32) was only 5-10 g overweight, the expression levels of the proSAAS-derived peptides in mice derived from this founder were only 60-90% above the Tg littermates, suggesting that a reasonably small increase in these peptides has a significant effect on body weight. In addition to the correlation between proSAAS expression and obesity in the three founder mice noted above, line 32 itself served as its own control; during the backcrossing of the proSAAS transgene into the BKS background, some of the Tg + offspring failed to express the proSAAS-derived peptides and these mice were no longer overweight relative to Tg littermates (data not shown). In addition, when crossed into the Cpe fat/fat mice, the Tg + mice that no longer expressed the proSAAS-derived peptides survived through 35 weeks (data not shown). Thus, even though the proSAAS transgene was still present in the genome, and any interrupted gene would still be inactivated, the mice that lost the expression of the proSAAS protein also lost the increased body weight phenotype (in the Cpe +/+ mice) and the adolescent-onset mortality (in the Cpe fat/fat mice). Taken together, these results support the hypothesis that proSAAS and/or proSAAS-derived peptides function in the regulation of body weight, either as inhibitors of PC1 activity or directly as neuropeptides. 
